Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.53 |
| ▸ | GPR39 | O43194 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PANK3 | Q9H999 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287978 | 0.88 | DRD2 (0.53) | SMOGPR39PDE3BPDE3APARP1 | |
| SCHEMBL19748777 | 0.84 | DRD2 (0.50) | SMOGPR39PDE3BPDE3APARP1 | |
| SCHEMBL3592250 | 0.83 | KDM4E (0.54) | SMOKDM4EPANK3ALDH1A1L3MBTL1 | |
| SCHEMBL15271400 | 0.82 | GAA (0.52) | SMOGPR39PDE3BPDE3APARP1 | |
| SCHEMBL16627261 | 0.82 | RET (0.52) | SMOGPR39PDE3BPDE3APARP1 | |
| SCHEMBL10576298 | 0.81 | SMO (0.48) | SMOGPR39PDE3BPDE3APARP1 | |
| SCHEMBL28750639 | 0.81 | GPR39 (0.50) | SMOGPR39PDE3BPDE3APARP1 | |
| SCHEMBL3048925 | 0.80 | KDM4E (0.54) | SMOKDM4EPANK3ALDH1A1L3MBTL1 | |
| SCHEMBL14844043 | 0.80 | SMO (0.56) | SMOKDM4EPANK3ALDH1A1L3MBTL1 | |
| SCHEMBL29514660 | 0.80 | KDM4E (0.54) | SMOKDM4EPANK3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023141290-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-7528135-B2 | Pyridine derivatives as H3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1824829-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | disclosed |
| WO-2006058649-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | HRH3, HRH4, HRH2 | SMO 770/4885GPR39 104/4885PDE3B 1618/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | SMO 1817/4885GPR39 423/4885PDE3B 3833/4885 |
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | SMO 1435/4885GPR39 467/4885PDE3B 293/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | SMO 2562/4885GPR39 1094/4885PDE3B 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.